Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 6/20 | 0.85 |
| ▸ | MCHR2 | Q969V1 | 2/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.66 |
| ▸ | LMNA | P02545 | 3/20 | 0.65 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.60 |
| ▸ | PKM | P14618 | 1/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6109038 | 0.94 | MCHR1 (0.90) | MCHR1MCHR2ALDH1A1LMNAMAPT | |
| SCHEMBL6109229 | 0.93 | MCHR1 (0.77) | MCHR1MCHR2ALDH1A1LMNAMAPT | |
| SCHEMBL6109146 | 0.92 | MCHR1 (1.00) | MCHR1MCHR2ALDH1A1LMNAMAPT | |
| SCHEMBL6108922 | 0.92 | MCHR1 (0.73) | MCHR1MCHR2ALDH1A1LMNAEPHX2 | |
| SCHEMBL6109418 | 0.91 | MCHR1 (0.93) | MCHR1MCHR2ALDH1A1LMNA | |
| SCHEMBL6109289 | 0.91 | MCHR1 (0.77) | MCHR1MCHR2ALDH1A1LMNAMAPT | |
| SCHEMBL6109770 | 0.91 | MCHR1 (0.77) | MCHR1MCHR2ALDH1A1LMNAMAPT | |
| SCHEMBL6110331 | 0.88 | MCHR1 (0.81) | MCHR1MCHR2ALDH1A1LMNAEPHX2 | |
| SCHEMBL6109186 | 0.88 | MCHR1 (0.70) | MCHR1MCHR2ALDH1A1LMNAMAPT | |
| SCHEMBL6110505 | 0.88 | MCHR1 (1.00) | MCHR1MCHR2ALDH1A1MAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060235035-A1 | Novel methoxybenzamibe compounds for use in mch receptor related disorders | 7TM PHARMA A/S (DK) | 2006-10-19 | — | — | US | disclosed |
| WO-2004048319-A1 | NOVEL BENZAMIDE COMPOUNDS FOR USE IN MCH RECEPTOR RELATED DISORDERS | 7TM PHARMA A/S (DK) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060235035-A1 | Novel methoxybenzamibe compounds for use in mch receptor related disorders | GPR119, MCHR2, HCRTR2 | MCHR1 5/4885MCHR2 2/4885ALDH1A1 3618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.